Vigabatrin(Sabril)

Sabril is a prescription drug developed in the 1980s and first approved and marketed in the United Kingdom in 1996. Its target is γ‑aminobutyric acid (GABA) transaminase. It should be used strictly under medical supervision.

Target of Action

Gamma-aminobutyric acid (GABA) aminotransferase

Dosage and Administration

The dosage of vigabatrin should be adjusted according to the patient’s actual condition. For specific details, please consult a doctor and strictly follow medical advice.

Recommended Reading: Dosage and Administration of Vigabatrin

Side Effects

Major Risks and Warnings: May cause permanent vision loss.

Common Side Effects: Blurred vision, drowsiness, dizziness, etc.

Serious Side Effects: Decreased red blood cell count (anemia), drowsiness, fatigue, etc.

Reference Article: Side Effects of Vigabatrin

Use in Special Populations

Pregnancy: If you are pregnant or planning to become pregnant, Sabril may cause harm to the fetus. Please inform your healthcare provider if you are pregnant or intend to conceive. You should decide with your healthcare provider whether to continue taking Sabril during pregnancy.

Lactation: If you are breastfeeding or planning to breastfeed, Sabril can pass into breast milk and may cause harm to your baby. Breastfeeding is not recommended. If you choose to breastfeed, closely monitor your baby for symptoms such as vision impairment, drowsiness, and weak sucking.

Daily Precautions

1. Before starting this medication, discuss with your healthcare provider how you or your child should handle a missed dose.

2. Take vigabatrin strictly as directed by your healthcare provider, usually twice daily.

3. Vigabatrin may be taken with or without food.

from FDA，2021.10